{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:45:59Z","timestamp":1793897159668,"version":"4.8.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Urinary tract infection (UTI) is a common cause of fever in children. Despite the increasing numbers of extended-spectrum beta-lactamase-producing organisms in the community, the empirical therapy of choice is still third-generation cephalosporins. This study was performed to investigate whether inappropriate empirical therapy (IAT) of community-onset UTI results in adverse clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We retrospectively studied a cohort of pediatric patients with first-episode community-onset UTI caused by <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>, <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic> and <jats:italic toggle=\"yes\">Proteus<\/jats:italic> spp. at Ramathibodi Hospital from 2011 to 2017. The patients were classified into IAT and appropriate empirical therapy (AT) groups. Medical records were reviewed to assess clinical outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One hundred fifty-one eligible patients were enrolled in this study. The most common causative organism was <jats:italic toggle=\"yes\">E. coli<\/jats:italic> (88.8% and 96.2% in the AT and IAT groups, respectively). Among the causative organisms, 19.8% were extended-spectrum beta-lactamase-producing organisms. There was no significant difference in clinical failure, microbiologic failure, relapse or time to defervescence between the 2 groups. No patients in either group developed sepsis after receiving empirical therapy. However, the length of hospital stay was significantly longer in the IAT than AT group [4.00 (4.50\u20136.00) vs. 7.00 (5.00\u201311.25) days, respectively; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.000].<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>No significant difference in treatment outcomes was found between pediatric patients receiving AT and IAT for the treatment of UTI. In the era of increasing antimicrobial resistance, third-generation cephalosporins may still be a good choice as an empirical antimicrobial for children diagnosed with community-onset UTI.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002515","type":"journal-article","created":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T19:32:36Z","timestamp":1574105556000},"page":"121-126","source":"Crossref","is-referenced-by-count":10,"title":["Outcomes of Empirical Antimicrobial Therapy for Pediatric Community-onset Febrile Urinary Tract Infection in the Era of Increasing Antimicrobial Resistance"],"prefix":"10.1097","volume":"39","author":[{"given":"Worawit","family":"Kantamalee","sequence":"first","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pitak","family":"Santanirand","sequence":"additional","affiliation":[{"name":"Clinical Microbiology Unit, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawaree","family":"Saisawat","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophida","family":"Boonsathorn","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonnamet","family":"Techasaensiri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nopporn","family":"Apiwattanakul","sequence":"additional","affiliation":[{"name":"Department of Pediatrics"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrmicro3432","article-title":"Urinary tract infections: epidemiology, mechanisms of infection and treatment options.","volume":"13","author":"Flores-Mireles","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3947\/ic.2013.45.4.415","article-title":"Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing enterobacteriaceae.","volume":"45","author":"Lee","year":"2013","journal-title":"Infect Chemother"},{"key":"R3-20230912","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1542\/peds.2011-1330","article-title":"Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months.","volume":"128","author":"Roberts","year":"2011","journal-title":"Pediatrics"},{"key":"R4-20230912","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/BF01641355","article-title":"Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.","volume":"11","author":"Knothe","year":"1983","journal-title":"Infection"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01644127","article-title":"Novel R-factor borne beta-lactamase of Escherichia coli confering resistance to cephalosporins.","volume":"15","author":"Bauernfeind","year":"1987","journal-title":"Infection"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jpeds.2013.06.078","article-title":"Urinary tract infections caused by community-acquired extended-spectrum \u03b2-lactamase-producing and nonproducing bacteria: a comparative study.","volume":"163","author":"Dayan","year":"2013","journal-title":"J Pediatr"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jmii.2013.05.006","article-title":"Rise of community-onset urinary tract infection caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli in children.","volume":"47","author":"Fan","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1128\/JCM.02111-09","article-title":"Laboratory surveillance for prospective plasmid-mediated AmpC beta-lactamases in the Kinki region of Japan.","volume":"48","author":"Yamasaki","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1186\/1471-2334-12-315","article-title":"Community faecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae in French children.","volume":"12","author":"Birgy","year":"2012","journal-title":"BMC Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"e0190910","DOI":"10.1371\/journal.pone.0190910","article-title":"Febrile urinary-tract infection due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: a French prospective multicenter study.","volume":"13","author":"Madhi","year":"2018","journal-title":"PLoS One"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3201\/eid1710.110655","article-title":"Global spread of carbapenemase-producing Enterobacteriaceae.","volume":"17","author":"Nordmann","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern.","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/ped.12845","article-title":"Pediatric extended spectrum \u03b2-lactamase infection: community-acquired infection and treatment options.","volume":"58","author":"Sethaphanich","year":"2016","journal-title":"Pediatr Int"},{"key":"R17-20230912","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.jiac.2017.04.006","article-title":"Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.","volume":"23","author":"Abe","year":"2017","journal-title":"J Infect Chemother"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2014.08.018","article-title":"Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.","volume":"29","author":"Asakura","year":"2014","journal-title":"Int J Infect Dis"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diagmicrobio.2017.07.011","article-title":"Long-term outcomes of inappropriate antibiotic therapy for upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a retrospective cohort study.","volume":"89","author":"Greenhouse","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/INF.0b013e318284b1e8","article-title":"Treatment of pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae in children.","volume":"32","author":"Katsuta","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijantimicag.2017.09.013","article-title":"Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum \u03b2-lactamase-producing enterobacteriaceae.","volume":"51","author":"Kim","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1093\/jac\/dku215","article-title":"The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum \u03b2-lactamase-producing Escherichia coli.","volume":"69","author":"Park","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2298\/SARH1206321P","article-title":"In vivo susceptibility of ESBL producing Escherichia coli to ceftriaxone in children with acute pyelonephritis.","volume":"140","author":"Peco-Anti\u0107","year":"2012","journal-title":"Srp Arh Celok Lek"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s10096-019-03528-9","article-title":"Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum \u03b2-lactamase-producing Enterobacteriales.","volume":"38","author":"Kim","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"222","DOI":"10.4103\/0974-777X.246391","article-title":"Extended-spectrum beta-lactamase-producing community-acquired urinary tract infections in children: chart review of risk factors.","volume":"10","author":"Balasubramanian","year":"2018","journal-title":"J Glob Infect Dis"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijantimicag.2019.04.007","article-title":"Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae infections.","volume":"54","author":"Tacconelli","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a Randomized Clinical Trial.","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:26:55Z","timestamp":1694557615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002515","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}